NCT02339571 2026-03-17A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced MelanomaNational Cancer Institute (NCI)Phase 2/3 Active not recruiting600 enrolled
NCT06581406 2026-02-18A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaReplimune Inc.Phase 2/3 Recruiting280 enrolled